Literature DB >> 15588870

Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?

Olga Vrieze1, Karin Haustermans, Walter De Wever, Toni Lerut, Eric Van Cutsem, Nadine Ectors, Martin Hiele, Patrick Flamen.   

Abstract

BACKGROUND AND
PURPOSE: To determine the additional value of FDG-positron emission tomography (PET) to optimize delineation of the clinical target volume (CTV) in patients with advanced esophageal carcinoma. METHODS AND MATERIALS: The imaging and radiotherapy data from 30 patients with an advanced esophageal carcinoma were analysed. The lymph node classification for esophageal cancer was modified and translated into anatomical volumes on computed tomography (CT). The so defined 14 different regions were scored individually for lymph node involvement on CT, endoscopic ultrasound (EUS) and FDG-PET. The influence of discordant findings between conventional and functional imaging on the decision as to what should be irradiated was assessed.
RESULTS: In 14 of the 30 patients (47%) discordances were found in detection of the pathological lymph nodes between CT/EUS and FDG-PET. In 8 patients, 9 lymph node regions were found with pathologic nodes on conventional imaging only. In three of these patients the influence of FDG-PET findings would have led to a decrease of the irradiated volume. In 6 patients, 8 lymph node regions were found with a normal CT/EUS and pathologic nodes on FDG-PET. In three of these patients (10%) the influence of the FDG-PET would have led to enlargement of the irradiated volume.
CONCLUSIONS: The chance of a false negative result on FGD-PET is not negligible; therefore, the irradiated volume should not be reduced based on a negative FDG-PET in a region with suspect nodes on other investigations. However, due to the high specificity of FDG-PET enlarging the irradiated volume based on a positive FDG-PET in a region without suspected lymph nodes on CT and/or EUS should be considered. This indicates a role for FDG-PET in radiotherapy planning for esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15588870     DOI: 10.1016/j.radonc.2004.10.001

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  27 in total

1.  Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.

Authors:  Andre Konski; Tianyu Li; Michael Christensen; Jonathan D Cheng; Jian Q Yu; Kevin Crawford; Oleh Haluszka; Jeffrey Tokar; Walter Scott; Neal J Meropol; Steven J Cohen; Alan Maurer; Gary M Freedman
Journal:  Radiother Oncol       Date:  2012-06-07       Impact factor: 6.280

Review 2.  PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques.

Authors:  Habib Zaidi; Issam El Naqa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-25       Impact factor: 9.236

Review 3.  Technological advances in radiotherapy for esophageal cancer.

Authors:  Milan Vosmik; Jiri Petera; Igor Sirak; Miroslav Hodek; Petr Paluska; Jiri Dolezal; Marcela Kopacova
Journal:  World J Gastroenterol       Date:  2010-11-28       Impact factor: 5.742

4.  The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.

Authors:  Tracy Klayton; Tianyu Li; Jian Q Yu; Lanea Keller; Jonathan Cheng; Steven J Cohen; Neal J Meropol; Walter Scott; Meng Xu-Welliver; Andre Konski
Journal:  J Gastrointest Cancer       Date:  2012-12

Review 5.  Positron emission tomography imaging approaches for external beam radiation therapies: current status and future developments.

Authors:  P M Price; M M Green
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

6.  [Neoadjuvant therapy for squamous cell carcinoma of the esophagus].

Authors:  F Lordick
Journal:  Chirurg       Date:  2005-11       Impact factor: 0.955

Review 7.  The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment.

Authors:  Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

8.  Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites?

Authors:  Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04       Impact factor: 9.236

9.  Radiotherapy volume delineation using 18F-FDG-PET/CT modifies gross node volume in patients with oesophageal cancer.

Authors:  E Jimenez-Jimenez; P Mateos; N Aymar; R Roncero; I Ortiz; M Gimenez; J Pardo; J Salinas; S Sabater
Journal:  Clin Transl Oncol       Date:  2018-05-02       Impact factor: 3.405

10.  Prospective comparison of optic versus blind endoscopic ultrasound in staging esophageal cancer.

Authors:  Christopher P Twine; Wyn G Lewis; Xavier Escofet; David Bosanquet; S Ashley Roberts
Journal:  Surg Endosc       Date:  2009-05-14       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.